CervoMed Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CRVO | NGEN | NSB.AX | BIVI | CGTX | VYGR | |
|---|---|---|---|---|---|---|
| Market cap | 23.59M | 145.16M | 21.04M | 11.63M | 64.98M | 115.23M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.1 | -4.0 | — | -2.4 | -3.1 | -1.5 |
| Price/book | 0.9 | 4.3 | 1.4 | 1.0 | 2.0 | 0.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −78.60% | −41.30% | −65.52% | −10.67% | −58.86% | −55.69% |
| Today | +0.65% | +2.27% | 0.00% | −22.54% | −2.32% | +2.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All CRVO news ›CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
Silvercrest: Equinox reports approximately 10.3% stake
Client capital funded a shared Silvercrest (SAMG) stake with about $8.8M in purchases. Stock Titan - [SCHEDULE 13D/A] Silvercrest Asset Management Group Inc. Amended Major Shareholder Report Silvercrest: Equinox reports approximately 10.3%…
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the median 24-week biomarker data to be presented at…
CervoMed posts clinical and financial presentation
Investor conferences may feature CervoMed (CRVO)'s presentation on its business and clinical studies. Stock Titan CervoMed posts clinical and financial presentation Company representatives may use the presentation at conferences and…
Contrasting Merck & Co., Inc. (NYSE:MRK) and CervoMed (NASDAQ:CRVO)
Posted by Tristan Rich on Oct 8th, 2026 CervoMed (NASDAQ:CRVO – Get Free Report) and Merck & Co., Inc. (NYSE:MRK – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net2
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.